Surmodics, Inc. Logo

Surmodics, Inc.

SRDX

(0.8)
Stock Price

39,69 USD

-1.27% ROA

-9.56% ROE

-386.91x PER

Market Cap.

544.999.400,00 USD

25.85% DER

0% Yield

-9.15% NPM

Surmodics, Inc. Stock Analysis

Surmodics, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Surmodics, Inc. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a low debt to equity ratio (30%), which means it has a small amount of debt compared to the ownership it holds

2 Buffet Intrinsic Value

The company's stock shows potential as it is undervalued (112) according to Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

3 ROE

Negative ROE (-21.33%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-19.58%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 PBV

The stock's high Price-to-Book Value (P/BV) ratio (4.39x) suggests it's overvalued, potentially making it an expensive investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

9 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

10 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

11 Dividend

Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges.

Surmodics, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Surmodics, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Surmodics, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Surmodics, Inc. Revenue
Year Revenue Growth
1998 9.800.000
1999 13.500.000 27.41%
2000 18.279.000 26.14%
2001 22.693.000 19.45%
2002 29.488.000 23.04%
2003 43.232.000 31.79%
2004 49.738.000 13.08%
2005 62.381.000 20.27%
2006 69.884.000 10.74%
2007 73.164.000 4.48%
2008 97.051.000 24.61%
2009 121.534.000 20.14%
2010 69.898.000 -73.87%
2011 67.781.000 -3.12%
2012 51.928.000 -30.53%
2013 56.132.000 7.49%
2014 57.439.000 2.28%
2015 61.898.000 7.2%
2016 71.366.000 13.27%
2017 73.112.000 2.39%
2018 81.336.000 10.11%
2019 100.077.000 18.73%
2020 94.864.000 -5.5%
2021 105.136.000 9.77%
2022 99.951.000 -5.19%
2023 132.584.000 24.61%
2024 121.364.000 -9.24%
2024 126.078.000 3.74%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Surmodics, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1998 4.500.000
1999 5.200.000 13.46%
2000 6.797.000 23.5%
2001 7.997.000 15.01%
2002 9.714.000 17.68%
2003 11.790.000 17.61%
2004 12.633.000 6.67%
2005 16.072.000 21.4%
2006 20.391.000 21.18%
2007 28.465.000 28.36%
2008 40.498.000 29.71%
2009 24.379.000 -66.12%
2010 17.916.000 -36.07%
2011 30.656.000 41.56%
2012 14.143.000 -116.76%
2013 15.079.000 6.21%
2014 15.550.000 3.03%
2015 16.165.000 3.8%
2016 18.498.000 12.61%
2017 31.817.000 41.86%
2018 40.973.000 22.35%
2019 52.885.000 22.52%
2020 50.188.000 -5.37%
2021 46.734.000 -7.39%
2022 9.082.000 -414.58%
2023 9.572.000 5.12%
2024 39.060.000 75.49%
2024 10.000.000 -290.6%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Surmodics, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 3.100.000
1999 4.300.000 27.91%
2000 4.246.000 -1.27%
2001 4.690.000 9.47%
2002 6.382.000 26.51%
2003 8.153.000 21.72%
2004 7.099.000 -14.85%
2005 7.705.000 7.87%
2006 9.931.000 22.41%
2007 13.643.000 27.21%
2008 20.816.000 34.46%
2009 17.200.000 -21.02%
2010 18.451.000 6.78%
2011 20.545.000 10.19%
2012 14.025.000 -46.49%
2013 13.859.000 -1.2%
2014 15.297.000 9.4%
2015 18.025.000 15.13%
2016 18.000.000 -0.14%
2017 20.478.000 12.1%
2018 24.111.000 15.07%
2019 23.950.000 -0.67%
2020 28.392.000 15.65%
2021 30.677.000 7.45%
2022 46.935.000 34.64%
2023 0 0%
2024 66.508.000 100%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Surmodics, Inc. EBITDA
Year EBITDA Growth
1998 1.700.000
1999 3.300.000 48.48%
2000 6.555.000 49.66%
2001 7.566.000 13.36%
2002 10.709.000 29.35%
2003 20.640.000 48.12%
2004 10.474.000 -97.06%
2005 8.082.999 -29.58%
2006 39.873.000 79.73%
2007 18.882.000 -111.17%
2008 33.701.000 43.97%
2009 65.436.000 48.5%
2010 -12.841.000 609.59%
2011 40.167.000 131.97%
2012 19.307.000 -108.04%
2013 22.182.000 12.96%
2014 21.291.000 -4.18%
2015 21.894.000 2.75%
2016 26.411.000 17.1%
2017 12.931.000 -104.25%
2018 -1.101.000 1274.48%
2019 14.169.000 107.77%
2020 5.942.000 -138.46%
2021 12.172.000 51.18%
2022 -12.224.000 199.57%
2023 15.150.000 180.69%
2024 -12.972.000 216.79%
2024 1.188.000 1191.92%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Surmodics, Inc. Gross Profit
Year Gross Profit Growth
1998 9.300.000
1999 12.800.000 27.34%
2000 17.598.000 27.26%
2001 20.253.000 13.11%
2002 26.805.000 24.44%
2003 40.583.000 33.95%
2004 46.703.000 13.1%
2005 59.526.000 21.54%
2006 66.485.000 10.47%
2007 67.580.000 1.62%
2008 88.575.000 23.7%
2009 114.026.000 22.32%
2010 42.326.000 -169.4%
2011 59.466.000 28.82%
2012 44.510.000 -33.6%
2013 33.155.000 -34.25%
2014 33.873.000 2.12%
2015 37.114.000 8.73%
2016 41.960.000 11.55%
2017 29.873.000 -40.46%
2018 26.366.000 -13.3%
2019 33.553.000 21.42%
2020 29.359.000 -14.29%
2021 41.225.000 28.78%
2022 29.000.000 -42.16%
2023 61.024.000 52.48%
2024 84.092.000 27.43%
2024 93.052.000 9.63%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Surmodics, Inc. Net Profit
Year Net Profit Growth
1998 1.600.000
1999 4.400.000 63.64%
2000 4.240.000 -3.77%
2001 5.109.000 17.01%
2002 7.796.000 34.47%
2003 13.936.000 44.06%
2004 7.436.000 -87.41%
2005 -8.246.000 190.18%
2006 20.334.000 140.55%
2007 3.346.000 -507.71%
2008 14.739.000 77.3%
2009 37.550.000 60.75%
2010 -21.089.000 278.05%
2011 -12.778.000 -65.04%
2012 10.231.000 224.89%
2013 15.167.000 32.54%
2014 12.031.000 -26.07%
2015 13.447.000 10.53%
2016 9.985.000 -34.67%
2017 3.926.000 -154.33%
2018 -4.457.000 188.09%
2019 7.592.000 158.71%
2020 1.123.000 -576.05%
2021 4.237.000 73.5%
2022 -27.274.000 115.53%
2023 -1.536.000 -1675.65%
2024 -30.216.000 94.92%
2024 -11.542.000 -161.79%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Surmodics, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 0
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 1 0%
2004 0 0%
2005 0 0%
2006 1 100%
2007 0 0%
2008 1 0%
2009 2 100%
2010 -1 300%
2011 -1 0%
2012 1 0%
2013 1 100%
2014 1 0%
2015 1 100%
2016 1 0%
2017 0 0%
2018 0 0%
2019 1 0%
2020 0 0%
2021 0 0%
2022 -2 100%
2023 0 0%
2024 -2 100%
2024 -1 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Surmodics, Inc. Free Cashflow
Year Free Cashflow Growth
1998 1.300.000
1999 -300.000 533.33%
2000 4.383.000 106.84%
2001 5.758.000 23.88%
2002 1.309.000 -339.88%
2003 1.568.000 16.52%
2004 18.090.000 91.33%
2005 23.841.000 24.12%
2006 27.830.000 14.33%
2007 45.733.000 39.15%
2008 13.504.000 -238.66%
2009 1.957.000 -590.04%
2010 12.329.000 84.13%
2011 16.496.000 25.26%
2012 15.349.000 -7.47%
2013 15.746.000 2.52%
2014 15.907.000 1.01%
2015 13.144.000 -21.02%
2016 16.974.000 22.56%
2017 7.621.000 -122.73%
2018 19.960.000 61.82%
2019 1.290.000 -1447.29%
2020 10.339.000 87.52%
2021 9.110.000 -13.49%
2022 -20.593.000 144.24%
2023 7.596.000 371.1%
2024 -2.992.000 353.88%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Surmodics, Inc. Operating Cashflow
Year Operating Cashflow Growth
1998 2.100.000
1999 4.400.000 52.27%
2000 7.377.000 40.36%
2001 7.811.000 5.56%
2002 14.313.000 45.43%
2003 19.258.000 25.68%
2004 19.492.000 1.2%
2005 25.950.000 24.89%
2006 35.279.000 26.44%
2007 50.714.000 30.44%
2008 39.822.000 -27.35%
2009 31.321.000 -27.14%
2010 22.008.000 -42.32%
2011 19.955.000 -10.29%
2012 16.112.000 -23.85%
2013 17.665.000 8.79%
2014 18.185.000 2.86%
2015 15.021.000 -21.06%
2016 25.166.000 40.31%
2017 14.053.000 -79.08%
2018 34.052.000 58.73%
2019 8.038.000 -323.64%
2020 14.010.000 42.63%
2021 15.389.000 8.96%
2022 -17.223.000 189.35%
2023 10.514.000 263.81%
2024 -2.033.000 617.17%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Surmodics, Inc. Capital Expenditure
Year Capital Expenditure Growth
1998 800.000
1999 4.700.000 82.98%
2000 2.994.000 -56.98%
2001 2.053.000 -45.84%
2002 13.004.000 84.21%
2003 17.690.000 26.49%
2004 1.402.000 -1161.77%
2005 2.109.000 33.52%
2006 7.449.000 71.69%
2007 4.981.000 -49.55%
2008 26.318.000 81.07%
2009 29.364.000 10.37%
2010 9.679.000 -203.38%
2011 3.459.000 -179.82%
2012 763.000 -353.34%
2013 1.919.000 60.24%
2014 2.278.000 15.76%
2015 1.877.000 -21.36%
2016 8.192.000 77.09%
2017 6.432.000 -27.36%
2018 14.092.000 54.36%
2019 6.748.000 -108.83%
2020 3.671.000 -83.82%
2021 6.279.000 41.54%
2022 3.370.000 -86.32%
2023 2.918.000 -15.49%
2024 959.000 -204.28%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Surmodics, Inc. Equity
Year Equity Growth
1998 22.700.000
1999 29.700.000 23.57%
2000 48.303.000 38.51%
2001 55.700.000 13.28%
2002 69.995.000 20.42%
2003 86.114.000 18.72%
2004 94.504.000 8.88%
2005 115.581.000 18.24%
2006 145.203.000 20.4%
2007 130.922.000 -10.91%
2008 141.806.000 7.68%
2009 172.372.000 17.73%
2010 154.359.000 -11.67%
2011 145.336.000 -6.21%
2012 94.695.000 -53.48%
2013 93.817.000 -0.94%
2014 98.751.000 5%
2015 93.373.000 -5.76%
2016 106.833.000 12.6%
2017 111.557.000 4.23%
2018 108.610.000 -2.71%
2019 122.516.000 11.35%
2020 131.055.000 6.52%
2021 140.085.000 6.45%
2022 108.392.000 -29.24%
2023 119.910.000 9.61%
2024 118.144.000 -1.49%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Surmodics, Inc. Assets
Year Assets Growth
1998 24.300.000
1999 32.000.000 24.06%
2000 50.749.000 36.94%
2001 60.583.000 16.23%
2002 77.248.000 21.57%
2003 97.808.000 21.02%
2004 109.781.000 10.91%
2005 124.225.000 11.63%
2006 157.402.000 21.08%
2007 171.331.000 8.13%
2008 191.028.000 10.31%
2009 185.562.000 -2.95%
2010 170.279.000 -8.98%
2011 162.654.000 -4.69%
2012 103.870.000 -56.59%
2013 101.923.000 -1.91%
2014 104.889.000 2.83%
2015 100.210.000 -4.67%
2016 132.894.000 24.59%
2017 136.593.000 2.71%
2018 164.135.000 16.78%
2019 159.865.000 -2.67%
2020 168.763.000 5.27%
2021 194.592.000 13.27%
2022 158.359.000 -22.88%
2023 185.733.000 14.74%
2024 177.413.000 -4.69%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Surmodics, Inc. Liabilities
Year Liabilities Growth
1998 1.600.000
1999 2.300.000 30.43%
2000 2.446.000 5.97%
2001 4.883.000 49.91%
2002 7.253.000 32.68%
2003 11.694.000 37.98%
2004 15.277.000 23.45%
2005 8.644.000 -76.74%
2006 12.199.000 29.14%
2007 40.409.000 69.81%
2008 49.222.000 17.9%
2009 13.190.000 -273.18%
2010 15.920.000 17.15%
2011 17.318.000 8.07%
2012 9.175.000 -88.75%
2013 8.106.000 -13.19%
2014 6.138.000 -32.06%
2015 6.837.000 10.22%
2016 26.061.000 73.77%
2017 25.036.000 -4.09%
2018 55.525.000 54.91%
2019 37.349.000 -48.67%
2020 37.708.000 0.95%
2021 54.507.000 30.82%
2022 49.967.000 -9.09%
2023 65.823.000 24.09%
2024 59.269.000 -11.06%

Surmodics, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
8.53
Net Income per Share
-0.1
Price to Earning Ratio
-386.91x
Price To Sales Ratio
4.51x
POCF Ratio
-250.6
PFCF Ratio
-93.04
Price to Book Ratio
4.58
EV to Sales
4.59
EV Over EBITDA
450.53
EV to Operating CashFlow
-256.55
EV to FreeCashFlow
-94.6
Earnings Yield
-0
FreeCashFlow Yield
-0.01
Market Cap
0,54 Bil.
Enterprise Value
0,55 Bil.
Graham Number
4.3
Graham NetNet
0.33

Income Statement Metrics

Net Income per Share
-0.1
Income Quality
1.54
ROE
-0.01
Return On Assets
-0.06
Return On Capital Employed
-0.04
Net Income per EBT
1.54
EBT Per Ebit
1.33
Ebit per Revenue
-0.04
Effective Tax Rate
-0.54

Margins

Sales, General, & Administrative to Revenue
0.46
Research & Developement to Revenue
0.21
Stock Based Compensation to Revenue
0.07
Gross Profit Margin
0.66
Operating Profit Margin
-0.04
Pretax Profit Margin
-0.06
Net Profit Margin
-0.09

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.15
Free CashFlow per Share
-0.41
Capex to Operating CashFlow
-1.71
Capex to Revenue
0.03
Capex to Depreciation
0.42
Return on Invested Capital
-0.01
Return on Tangible Assets
-0.01
Days Sales Outstanding
72.68
Days Payables Outstanding
22.58
Days of Inventory on Hand
109.19
Receivables Turnover
5.02
Payables Turnover
16.16
Inventory Turnover
3.34
Capex per Share
0.26

Balance Sheet

Cash per Share
2,69
Book Value per Share
8,34
Tangible Book Value per Share
3.61
Shareholders Equity per Share
8.34
Interest Debt per Share
2.41
Debt to Equity
0.26
Debt to Assets
0.17
Net Debt to EBITDA
7.44
Current Ratio
3.98
Tangible Asset Value
0,05 Bil.
Net Current Asset Value
0,02 Bil.
Invested Capital
155769000
Working Capital
0,06 Bil.
Intangibles to Total Assets
0.38
Average Receivables
0,02 Bil.
Average Payables
0,00 Bil.
Average Inventory
15405000
Debt to Market Cap
0.06

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Surmodics, Inc. Dividends
Year Dividends Growth

Surmodics, Inc. Profile

About Surmodics, Inc.

Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for coronary, peripheral, neuro-vascular and structural heart, and other markets, as well as design, development, and manufacturing of interventional medical devices, primarily balloons and catheters, including drug-coated balloons for peripheral arterial disease treatment and other applications. The IVD segment designs, develops, and manufactures component products and technologies for diagnostic immunoassay, as well as molecular test and biomedical research applications. This segment offers protein stabilization reagents, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.

CEO
Mr. Gary R. Maharaj
Employee
376
Address
9924 West 74th Street
Eden Prairie, 55344-3523

Surmodics, Inc. Executives & BODs

Surmodics, Inc. Executives & BODs
# Name Age
1 Mr. John D. Manders
Corporate Controller, Vice President of Finance & Principal Accounting Officer
70
2 Mr. Joseph J. Stich
Senior Vice President of Human Resources & President of In Vitro Diagnostics
70
3 Mr. Timothy J. Arens
Senior Vice President of Finance & Information Technology and Chief Financial Officer
70
4 Mr. Charles W. Olson
Senior Vice President & President of Medical Device Coatings
70
5 Mr. Gary R. Maharaj
Chief Executive Officer, President & Director
70
6 Joel Suiter
Director of Corporate Development
70

Surmodics, Inc. Competitors

ProSomnus, Inc. Logo
ProSomnus, Inc.

OSA

(2.2)
LivaNova PLC Logo
LivaNova PLC

LIVN

(2.2)
Electromed, Inc. Logo
Electromed, Inc.

ELMD

(2.0)
NeuroPace, Inc. Logo
NeuroPace, Inc.

NPCE

(0.5)
Inogen, Inc. Logo
Inogen, Inc.

INGN

(1.2)
Pulmonx Corporation Logo
Pulmonx Corporation

LUNG

(1.2)
NuVasive, Inc. Logo
NuVasive, Inc.

NUVA

(1.0)
CONMED Corporation Logo
CONMED Corporation

CNMD

(1.5)
SI-BONE, Inc. Logo
SI-BONE, Inc.

SIBN

(1.0)
AxoGen, Inc. Logo
AxoGen, Inc.

AXGN

(1.2)
Paragon 28, Inc. Logo
Paragon 28, Inc.

FNA

(1.5)